RHINOMED

ASX: RNO

SLEEP AND NASAL RESPIRATORY SOLUTIONS FROM THE COUNTER TO THE CLINIC

AGM - NOVEMBER 14TH, 2017

IMPORTANT NOTICE

This document contains certain forward-looking statements, relating to Rhinomed Limited's (Rhinomed) business which can be identified by the use of forward looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of the company's technologies and products. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy any specific health authority and other health authorities requirements regarding any one or more product or technology nor can there any assurance that such products or technologies will be approved by any health authorities for sale in any markets or that they will reach any particular level of sales. In particular, managements expectations regarding the approval and commercialization of the technology could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, technology, financial result, and business prospects. Should one of more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Rhinomed Is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

DELIVERING ON MAJOR MILESTONES AND POISED FOR GROWTH

Positioned in the rapidly growing sleep and respiratory medicine markets, Rhinomed has achieved commercial validation and strong retail acceptance with global consumer health retailers.

EXCITING PLATFORM TECHNOLOGY

- 1. Two products already in market
- 2. Two products in development
- 3. Multiple next generation technology applications

4

SIGNIFICANT OPPORTUNITY TO SCALE GLOBALLY

- 1. Already on shelf in over 7000 stores in Aust, UK, Canada and USA
- 2. Business development pipeline of 15,000+ stores in US alone
- 3. Opportunity for retail expansion in Europe and Asia.

2 COMPREHENSIVE IP PORTFOLIO

- 1. Over 60 patents covering multiple applications
- 2. 57 Design patents
- 3. Brands and trademarks

5

GROWING REVENUE LINES

- 1. Strong existing retail channels
- 2. Well established production and logistic network
- 3. Strong gross margins
- 4. Addressing needs of 90 million American snorers and the one in four people suffering from nasal obstruction



ESTABLISHED SCIENCE AND EXCITING NEXT GEN OSA PROGRAM

- 1. Leveraging existing research in role of the nose and respiration
- 2. Positive Phase 1 Trial results for Next Gen Obstructive Sleep Apnea Therapy

6

COMPELLING CONSUMER HEALTH BRANDS IN GROWING GLOBAL MARKETS

- 1. Turbine global sport and exercise market
- 2. Mute OTC consumer health and sleep markets
- 3. Emerging interest as companion therapy in existing sleep apnea market

"I'm a huge fan of your product. It has changed my life! I sleep like a baby and run like an iron man."

DELIVERING YEAR ON YEAR INCOME GROWTH

- Steady growth in units shipped to customers
- Total units shipped FY17 YTD approx. 150,000
- FY17 Revenue generated from installed store base of approximately 2800 stores



DELIVERING YEAR ON YEAR STORE GROWTH



- Three fold increase in store count
- Footprint in Australia, UK, Canada and USA
- FY 18 Target footprint of 15,000 stores
- Strong pipeline of additional 20,000 stores

WE STARTED FY17 IN NORTH AMERICA WITH 1000 STORES



12 MONTHS LATER - 5500+ STORES NATIONWIDE AND GROWING



THE MOMENTUM CONTINUES INTO FY18 QUARTER 1

- Record number of units shipped during Q1 FY18
 - 52,000 (33% of entire last FY)
- Revenue
 - o (Revenue) Invoiced \$592k
 - Revenue recognised \$307k (up 30%)
- Store count
 - Over 7000 stores stocking Mute
 - Mute accessible through additional 13,000 stores
 - Walgreen's stocked Mute into 4300 new stores in early October
- Strong pipeline of new stores:
 - o UK Pheonix (3550 stores)
 - o US 10,000
 - o Australia 1500

NASAL OBSTRUCTION - COMPROMISING SLEEP AND RESPIRATION

One in four people suffer from some form of nasal obstruction.

- Nasal obstruction is a contributor to snoring and poor sleep
- Mouth breathing can lead to poor sleep and Sleep Disordered Breathing issues
- Poor sleep and snoring is now being directly linked to Alzheimer Disease and other neurocognitive disorders
- People with nasal congestion are twice as likely to have moderate to severe sleep apnea



LEVERAGING PHYSICS TO ADDRESS NASAL OBSTRUCTION

- The diameter of your nose matters
- 50% of airway resistance occurs in the nose. A small change in the radius of the nose can dramatically impact the volume of air entering the airway.
- Poiseuille's Law if the radius of the nose increases by 1, the volume of air traveling through the airway increases 16 times

- to the power of 4.

• Mute and Turbine leverage Poiseuille's Law to deliver a significant improvement in nasal patency and efficacy



Poiseuille's Law

Q	Flow rate	
Р	Pressure	
r	Radius	
η	Fluid viscosity	
1	Length of tubing	



Proprietary ratchet mechanism that delivers perfect individualised fit gently expands the nostril delivering airflow to the power of 4



Dilates from the back of the nose minimising pressure on the septum Designed to mold to the internal surface of the nostril

MUTE IS NOW AN EMERGING GLOBAL CONSUMER HEALTH BRAND

- Adjustable for each nostril to ensure ultimate comfort and fit
- Available in a trial pack (contains 3 different sizes) and three sizes (small, medium & large)
- Reusable up to 10 times, thus small, medium & large pack lasts 30 days
- RRP US\$24.95 delivering strong margins



GROWING CUSTOMER SUPPORT & ENGAGEMENT

I CAN BREATHE

By Mike April 22, 2017 I can breathe again, love this product as it gently opens nasal passages and preventing airway collapse, letting me BREATHE!!!

SO AWESOME!

By John M Langston March 31, 2016

These things work amazing. How I slept with these encouraged me to finally have my deviated septum repaired.

WOW

By Jon February 7, 2017

These are absolutely amazing. I have never been able to breathe from my nose the way I can while wearing this device. It literally feels like I got corrective nose surgery. They stay nice and secure while sleeping. For the price, it is amazing what this does for nose breathing, don't even notice them anymore, besides the ability to actually breathe from my nose for once. Highly recommend this

GREAT FOR STUFFY NOSES!

By Imstillhere September 14, 2016 Great product! Much better than the tunnel products,

SNORING IS DOWN TO A RUMBLE... By Mike T August 21, 2016

Snoring is down to a rumble, no stops in breathing, more rested, and my wife was able to ditch the ear plugs.

SO SIMPLE, WHY OH WHY DID IT TAKE ME...

By Ann June 16, 2017

So simple, why oh why did it take me so long to find these. I have tried everything short of a cpap machine. This actually works and is by far more comfortable than any mouthguard solution.

WORKS AMAZINGLY WELL!

By Linda K. Horton May 21, 2016 I have finally found a product that works! I used the strips for years but disliked that I would have an indentation every morning when I would take it off plus the fact that it sometimes take my skin off with it. Mute has been perfect!

AIR!!!!!!

By David December 1, 2016 Why did I only discover this product now?!!!! As soon as I placed Mute in, I could breathe! I was amazed how much air I was taking in. It was super comfortable and didn't fall out when I was sleeping. I didn't know breathing could be so satisfying. GEN 2.0 – IN DEVELOPMENT NASAL TECHNOLOGY – OLFACTORY PATHWAY

DISRUPTIVE SOLUTION FOR THE US\$8BILLION DECONGESTION MARKET



MUTE 'CLEAR'

- Mute with added 'menthol/ eucalypt' formulation
- Next generation multi formulation platform
- Delivers low dose, overnight nasal decongestant
- Disruptive innovation in a market Vicks has dominated for decades
- Class 1 product regulatory process scoped
- Design being finalised and production scoping underway

DISRUPTIVE SOLUTION FOR THE US\$3BILLION AROMATHERAPY MARKET

MUTE 'DEEP SLEEP'

- Mute with added 'lavender/chamomile' formulation
- Delivers low dose, overnight nasal relaxant to tackle anxiety, sleep onset and poor sleep maintenance
- Disruptive delivery technology in the aromatherapy market
- Class 1 product regulatory process scoped
- Design being finalised and production scoping underway



INPEAP – A DISRUPTIVE, LOW INVASIVE SOLUTION FOR OBSTRUCTIVE SLEEP APNEA

INTRA NASAL POSITIVE EXPIRATORY AIRWAY PRESSURE (INPEAP) TECHNOLOGY

- A new patented alternative to CPAP and mandibular advancement technologies
- Targeting the 70% of OSA patients with Mild to moderate OSA - (AHI 14-29)
- Internal nasal delivery of Positive Expiratory Airway Pressure to keep airway open during sleep
- Low invasive solution when compared to CPAP and Oral devices
- Successfully completed Phase 1 trial showing
 - Nasally delivered EPAP
 - Well tolerated 73% compliance
 - Leverages the growing acceptance of Mute



NEXT GENERATION OF WEARABLE NASAL SENSOR TECHNOLOGY

Adoption of the platform to measure a variety of both organic and inorganic substances:

For example:

- Nitric Oxide measurement of NO as a bio-marker for asthma, COPD and other respiratory diseases
- SpO2 Alar pulse oximetry
- Nasal air pressure a critical data channel in measuring the existence and severity of Sleep Apnea



NEXT GENERATION NASAL DRUG DELIVERY - SEEKING PARTNERSHIP



Opening up a new window for nasal drug delivery

- In situ delivery
- Low dose, long release
- High dose, quick onset
- Providing an innovative platform for multiple targets
- Existing solutions significantly de-risk acceptance and adoption of a drug delivery solution – compliance
- Potential Targets:
 - o Triptans for Migraine
 - Cannabinoids for pain relief and sleep
 - Topical decongestants and antihistamines

SLEEP - A MARKET RIPE FOR DISRUPTION

IN THE HOME

- Sleep measurement has become a commodity
- Hundreds of wearables and devices all measure sleep in various ways
- Consumers are left feeling "so what?"
- People 'know' when they sleep poorly,
- But the question remains on what to do and how to solve this.

IN THE CLINIC

- 80% with sleep apnea remain undiagnosed
- Only 40% of those being treated with CPAP are compliant
- CPAP is costly (<\$2000) and delivers a sub optimal patient outcome
- Clinicians are starved of innovation and the ability to offer patients a range of solutions that meet patients individuals specific needs
- Sleep medication (drug) suffers from a well deserved stigma

THE PHARMACY

- Pharmacies provide primary healthcare to millions world wide, but little in the way of sleep solutions
- OTC Sleep category is in its infancy
- Pharmacies will become the starting point for patients looking for sleep solutions
- This will allow millions of patients to access a range of low cost, 'non drug', low invasive solutions that will solve, either solus or in combination, their sleep needs from primary snoring through to complex insomnia and sleep apneas
- The global sleep aid and sleep apnea market is set for <u>seismic change</u> driven by a desperate need for better patient and health economic outcomes.
- Awareness of the importance of sleep has never been greater.
- The link between poor sleep and chronic disease has never been clearer.
- Pharmacies will play an ever increasingly important role as the entry point for sleep solutions
- ONLY Rhinomed's "Counter to the clinic" approach has created a portfolio of solutions designed to address the specific needs of patients at every stage of the sleep spectrum and through multiple distribution channels.



RHINOMED WILL OWN SLEEP FROM THE 'COUNTER TO THE CLINIC'

Growing acceptance of Mute and Turbine significantly de-risks our later stage innovation program

1.0		2.0		3.0	4.0	5.0
SPORT	SNORING AND SLEEP	DECONGESTION	ANXIETY	OBSTRUCTIVE SLEEP APNEA	DIAGNOSTICS	NASAL DRUG DELIVERY
		Menthol Eucalypt formulation Mute "CLEAR"	Essential oil formulation Mute "DeepSleep"	Intranasal Positive Expiratory Airway Pressure Phase 1 trial complete, Phase 2 being scoped	Addition of Sensor to detect Nitric Oxide(No) and nasal air pressures	Target low dose, long release delivery of drugs to nasal mucosa. to resolve Sleep issues, Pain, CNS, Respiratory disorders
	RKET		- IN DEVELOPM	ENT		

CORPORATE SUMMARY

GLOBALLY EXPERIENCED BC	OARD OF DIRECTORS	ASX: RNO		
Mr Ron Dewhurst - Chairman	Previously Head of Americas JP Morgan Asset Management, EVP Head of Global Investment Managers Legg Mason Inc, CEO IOOF Holdings Ltd. Currently Director OneVue Ltd, Sprott Inc.	FY17 Financial Position	Receipts FY17 - \$2.02m Units shipped FY17 YTD - 150,000 Strong Gross Margins	
Mr Michael Johnson – CEO and Managing Director	CEO and MD since February 2013, Director Cogentum Advisory, Previously Director Cetus Energy, Principal Strategyn		Top 20 - 47% Market Cap - approx A\$20m Shares on issues - 93m	
Mr Brent Scrimshaw - Non Exec Director	Previously VP & CEO Nike Western Europe, VP & CMO Nike Europe, Middle East & Africa, GM Nike USA (East), CMO Nike Australia and NZ. Currently Non Exec Director Catapult Ltd (ASX: CAT) and CEO Unscript'd Pty Ltd Previously Lawyer Baker McKenzie, Consultant Boston Consulting Group. Currently Strategy Professor & Pro-Vice- Chancellor University of Sydney	Capital Structure		
		Offices	Melbourne, Australia and	
Dr Eric Knight - Non Exec Director		Unices	Cincinnati, USA	

INVESTMENT PROPOSITION



• Purchased by GSK -US\$566m in 2007

CHRIS FROOME

TOUR DE FRANCE WINNER 2013, 2015, 2016 & 2017



MICHAEL JOHNSON, CEO e. mjohnson@rhinomed.global t. +61 3 8416 0900 www. rhinomed.global

RHINOMED